Abstracts tagged "proteomics and systemic sclerosis"

Abstract Number: 1103 • 2018 ACR/ARHP Annual Meeting
Systemic Sclerosis Has a Distinct Serum Protein Profile That Correlates with Its Clinical Manifestations
Chiara Bellocchi^1,2, Jun Ying³, Ellen Goldmuntz⁴, Lynette Keyes-Elstein⁵, John Varga⁶, Monique Hinchcliff⁶, Peter McSweeney⁷, Daniel E. Furst⁸, Richard Nash⁷, Leslie Crofford⁹, Beverly Welch¹⁰, Ashley Pinckney⁵, Maureen D. Mayes^11,12, Keith Sullivan¹³ and Shervin Assassi¹², ¹University of Texas Health Science Center at Houston, Houston, TX, ²Scleroderma Unit, Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, ³Department of Internal Medicine - Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁴NIAID, National Institutes of Health, Bethesda, MD, ⁵Rho Federal Systems, Inc., Chapel Hill, NC, ⁶Northwestern University, Chicago, IL, ⁷Colorado Blood Cancer Institute, Denver, CO, ⁸University of California Los Angeles, Los Angeles, CA, ⁹Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ¹⁰National Institutes of Health, Bethesda, MD, ¹¹Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ¹²Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ¹³Duke University Medical Center, Durham, NC
Background/Purpose: Proteomic studies with an extensive panel of measured proteins are still scarce in systemic sclerosis (SSc). The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial showed…
Abstract Number: 769 • 2017 ACR/ARHP Annual Meeting
Proteomic Analysis of Human Fibroblasts in Systemic Sclerosis Reinforces the Role of Transforming Growth Factor-ß and Points Toward Epidermal Growth Factor Receptor / Phosphatidylinositol 3 Kinase Pathway Inhibition
Benjamin Chaigne¹, Guilhem Clary², Morgane Le Gall³, Nicolas Dumoitier⁴, Sebastien Lofek⁵, Philippe Chafey², Pia Moinzadeh⁶, Thomas Krieg⁷, Christopher Denton⁸ and Luc Mouthon⁹, ¹Service de Médecine Interne, Centre de Référence Maladies Systémiques Autoimmunes Rares d’Ile de France, hôpital Cochin, DHU Authors, Assistance Publique-Hôpitaux de Paris, Paris, France, ²INSERM U1016, Institut Cochin,, Paris, France, ³INSERM U1016 Institut Cochin, Paris, France, ⁴INSERM U1016, Institut Cochin, Equipe Neutrophiles et Vascularites, Paris, France, ⁵INSERM U1016, paris, France, ⁶Department of Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁷Universität zu Köln, Köln, Germany, ⁸Department of Rheumatology, University College London, Royal Free Hospital, London, United Kingdom, ⁹Service de Médecine Interne, Hôpital Cochin, Centre de référence national pour les maladies systémiques autoimmunes rares d’Ile de France, DHU Authors, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France ;Université Paris Descartes Sorbonne Paris, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a rare autoimmune connective tissue disorder characterized by autoimmunity, vasculopathy and fibrosis. Fibrosis is due to an exaggerated activation of…
Abstract Number: 1917 • 2015 ACR/ARHP Annual Meeting
Developing and Validating a Serum Biomarker for the Extent of Skin Disease in Patients with Diffuse Cutaneous Systemic Sclerosis
Lisa Rice¹, Julio Mantero², Giuseppina Stifano¹, Jessica Ziemek³, Robyn T. Domsic⁴ and Robert Lafyatis¹, ¹Boston University School of Medicine, Boston, MA, ²Rheumatology, Boston University School of Medicine, Boston, MA, ³Rheumatology/Arthritis Center, Boston University School of Medicine, Boston, MA, ⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: In this study we aimed to both agonistically investigate alterations in the serum proteome of patients with diffuse cutaneous systemic sclerosis (dcSSc), as well…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].